Oncology | Phase I/ Phase II Developments | NORWAY

Nordic Nanovector

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Nordic Nanovector - Mature Data from the LYMRIT 37-01 - Part A trial, Published in Blood Advances

Lead Product(s): Lutetium (177Lu)-lilotomab satetraxetan

Therapeutic Area: Oncology Product Name: Betalutin

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 03, 2020

Details:

The data presented in this paper are aligned with the preliminary results presented by Dr Kolstad at the American Society of Hematology medical conference in December 2018:Overall response rate (ORR) was 61% and complete response (CR) was 30% for all 74 patients.

BerGenBio ASA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

BerGenBio Doses First Patient in Recurrent Glioblastoma Investigator Sponsored Ph I/II Study Assessing Selective AXL Inhibitor Bemcentinib

Lead Product(s): Bemcentinib

Therapeutic Area: Oncology Product Name: BGB 324

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: University of Alabama

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2020

Details:

This is an open label, multi-centre, intra-tumoral tissue pharmacokinetic (PK) study of bemcentinib in patients with recurrent glioblastoma for whom a surgical resection is medically indicated.

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO

Lead Product(s): ONCOS-102,Durvalumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

Interim phase I data from the Phase I / II study of systemic durvalumab + intraperitoneal ONCOS-102 in peritoneal disease from ovarian or colorectal cancer will be presented at the ASCO20 conference.

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy

Lead Product(s): ONCOS-102,Cisplatin,Pemetrexed Disodium

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

The updated PFS data demonstrate enhanced immune activation and modulation of tumor microenvironment in ONCOS-102-treated patients compared to the control group.

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy

Lead Product(s): ONCOS-102,Cisplatin,Pemetrexed Disodium

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

Preliminary data show a numerical advantage in Progression Free Survival in ONCOS-102 treated patients.

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China

Lead Product(s): Apricoxib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: IOVaxis Therapeutics

Deal Size: $100.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 08, 2020

Details:

Under the agreement, IOVaxis and Targovax will jointly define a development plan in the territory, and IOVaxis will be responsible for all local regulatory filings and will sponsor clinical trials.

Find

Find Oncology Drugs in Phase I/II Clinical Development in NORWAY

Norway

Product Type

Companies

Nordic Nanovector

Nordic Nanovector - Mature Data from the LYMRIT 37-01 - Part A trial, Published in Blood Advances

BerGenBio ASA

BerGenBio Doses First Patient in Recurrent Glioblastoma Investigator Sponsored Ph I/II Study Assessing Selective AXL Inhibitor Bemcentinib

Targovax

Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO

Targovax

Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy

Targovax

Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy

Targovax

Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China